Sacroiliitis as an Initial Manifestation of Acute Myelogenous Leukemia

Abstract

Sacroiliitis is the most pathognomonic and earliest manifestation of ankylosing spondylitis.We herein report a 28-year-old female patient who presented with sacroiliitis as an initial manifestation of acute myelogenous leukemia (AML). She had a 3-month history of anemia and walking difficulty. Bone marrow findings revealed an increase of blasts with trilineage dysplasia. Although she was initially diagnosed with myelodysplastic syndrome (MDS), blasts rapidly increased and AML developed 1 month after the diagnosis of MDS with sacroiliitis. Induction chemotherapy failed to induce a complete remission of AML, but it did effectively treat the sacroiliitis. However, the sacroiliitis relapsed when the leukemia cells progressed thereafter. Oral corticosteroids helped ameliorate the sacroiliitis. She underwent bone marrow transplantation (BMT) from an HLA-identical sister during a nonremission period; however, the leukemic cells began to rapidly increase from day 30 after BMT. The close relationship between the occurrence of sacroiliitis and AML suggested that autoimmune sacroiliitis was a paraneoplastic phenomenon of AML in this patient. Although autoimmune disorders develop in a substantial number of MDS patients, they are rarely observed in de novo AML. No previous report has described sacroiliitis as the initial manifestation of de novo AML.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of New York criteria. Arthritis Rheum. 1984;27:361–368.

    Article  PubMed  Google Scholar 

  2. 2.

    Yamaguchi A, Tsuchiya N, Mitsui H, et al. Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of peptide-anchoring B pocket. Arthritis Rheum. 1995;38:1672–1677.

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Tanvetyanon T, Stiff P. Recurrent steroid-responsive pancreatitis associated with myelodysplastic syndrome and transformations. Leuk Lymphoma. 2005;46:151–154.

    Article  PubMed  Google Scholar 

  4. 4.

    Koch B, Kranzhofer N, Pfreundschu M, Pees HW, Trumper L. First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients. Bone Marrow Transplant. 2000;26:673–675.

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Bakland G, Nossent H. Acute myelogenous leukaemia following etanercept therapy. Rheumatology. 2003;42:900–917.

    Article  CAS  PubMed  Google Scholar 

  6. 6.

    Au WY, Hawkins BR, Cheng N, Lie AKW, Liang R, Kwong YL. Risk of haematological malignancies in HLA-B27 carriers. Br J Haematol. 2001;115:320–322.

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol. 1996;33:150–162.

    CAS  PubMed  Google Scholar 

  8. 8.

    Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol. 1995;91:403–408.

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Castro M, Conn DL, Su WP, Garton JP. Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol. 1991;18:721–727.

    CAS  PubMed  Google Scholar 

  10. 10.

    Billstrom R, Johansson H, Johansson B, Mitelman F. Immune-mediated complications in patients with myelodysplastic syndromes—clinical and cytogenetic features. Eur J Haematol. 1995;55:42–48.

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Okamoto T, Okada M, Mori A, et al. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol. 1997;66:345–351.

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA. Immunological abnormalities in myelodysplastic syndromes. Serum immunoglobulins and autoantibodies. Br J Haematol. 1986;63:143–147.

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Economopoulos T, Economidou J, Giannopoulos G, et al. Immune abnormalities in myelodysplastic syndromes. J Clin Pathol. 1985;38:908–911.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Takumi Hoshino or Takafumi Matsushima or Yasuyuki Saitoh or Arito Yamane or Makiko Takizawa or Hiroyuki Irisawa or Takayuki Saitoh or Hiroshi Handa or Norifumi Tsukamoto or Masamitsu Karasawa or Hirokazu Murakami or Yoshihisa Nojima.

About this article

Cite this article

Hoshino, T., Matsushima, T., Saitoh, Y. et al. Sacroiliitis as an Initial Manifestation of Acute Myelogenous Leukemia. Int J Hematol 84, 421–424 (2006). https://doi.org/10.1532/IJH97.06106

Download citation

Key words

  • Sacroiliitis
  • AML
  • AS